| E-Folder |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Strategic Planning > Risks to Business Success in China |
|
E-Folder - Risks to Business Success in China
USA companies have failed in China, because they underestimated the differences in doing business in China versus the USA, and th According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ey lacked a long-term commitment to be successful in China. China Business Environment – Prote ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ction of intellectual property can be challenging in China, along with maintaining USA standards for business conduct. Business l lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. aw and Chinese regulatory rules may be less clear than in the USA. The role of labor unions and works councils can be quite diffe here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe rent than most USA managers might expect, and requires understanding of Chinese cultural norms. China G d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro overnment Influence – While China has made tremendous progress encouraging development of a market-oriented economy, the ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc re are still important business decisions that must be made through collaboration with local governmental agencies. China partici easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi pation in the WTO has improved the ability of USA companies to operate in China, but this trend is an evolutionary process which nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically will take time to be fully effective. Due Diligence in China – USA businesses that fail to meet their goals in and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ China often do not fully consider whether their strategies and core competencies provide a basis for success in China. They may n ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ot fully evaluate external factors in China, such as competition, supply chain logistics, local technical and business expertise, ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a which may be critical to successful marketing or operations plan in China. Alignment of Strategic and Operational Plans dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod – The complexity of doing business in China requires a long-term strategy for success in China. However, while a long-t cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin erm roadmap is desirable, a step-by-step approach to entering China can minimize risks and maximize benefits of doing business in tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen China. Alignment of realistic implementation plans with long-term strategies that take into account the Chinese market environme t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel nt will reduce mistakes and frustration. The significant benefits of Chinese marketing and operations activity must be balanced a ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust gainst calculated risks of doing business in China. Local business partners can assist in investigating both the benefits and ris y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products k to your company. Exploratory business tours to China can provide valuable insight into Chinese market opportunities, and facili . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de tate meeting high level contacts that can be the beginning of building relationships with key partners to ensure your success in elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip China. Establishing “Guanxi” relationships with the right people in China will help ensure a successful venture for your business tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:What It Takes To Succeed In Business 8 Steps to Survive a Corporate Transfer Sales Training - Making It Stick
|